Globally this study provides encouraging evidence regarding the potential anti-tumor and immune-stimulatory properties of several 2LC1 capsules, and two of their actives; SNA-MYC (10 CH) and SNA-MYC (18 CH), on cancer cells and macrophages. This evidence concerns the gene MYC and neoplasm.